In this study, tumor explants of c-Met-positive HCC patients were, therefore, grafted onto immunocompromised mice to evaluate the tolerability and the antitumor and antimetastatic activity of MSC2156119J compared to sorafenib. Here, MET is linked to hepatocellular carcinoma.